Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of March 2026, with a report date of March 12, 2026. The document serves as a transaction notification detailing share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the Company's Share Reward Plan and Executive Supplemental Savings Plan.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific equity transactions.
| Transaction Type | Instrument | Price | Volume | Date |
|---|---|---|---|---|
| Share Reward Plan | Ordinary Shares (GB00BN7SWP63) | £20.7168 | 12 shares per executive | 2026-03-10 |
| Executive Savings Plan | American Depositary Shares (US37733W2044) | $55.5100 | 2.150 shares | 2026-03-09 |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document lists routine, initial notifications of share acquisitions by eight senior executives and one PCA. All Ordinary Share transactions occurred at the same price and volume structure (6 partnership shares and 6 matching shares).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of insider trading activity compliant with Rule 13a-16 or 15d-16.
Key Facts for Investor Verification
- Executive Participation: Verify the participation of key leaders including Lynn Baxter (President, Europe), Julie Brown (CFO), and Deborah Waterhouse (CEO, ViiV Healthcare) in the Share Reward Plan.
- Transaction Consistency: Confirm that all Ordinary Share acquisitions were executed on March 10, 2026, at a uniform price of £20.7168 on the London Stock Exchange.
- ADS Activity: Note the separate transaction by Maya Martinez-Davis (President, US) involving American Depositary Shares on the NYSE at $55.5100 on March 9, 2026.
- Scope Limitation: Acknowledge that this filing provides no data on GSK's overall financial performance for the period.